Addressing Alzheimer’s: A pragmatic approach

Family physicians are ideally positioned to support patients with Alzheimer’s and their families through all facets of the disease, from initial diagnosis to end-of-life care.

Alzheimer’s disease (AD), the most common form of dementia, affects more than 5 million Americans. Estimates suggest that by 2050, the prevalence could triple, reaching 13 to 16 million. To effectively care for patients with AD and their families, family physicians need to be familiar with the latest evidence on all facets of care, from initial detection to patient management and end-of-life care.

This evidence-based review will help you toward that end by answering common questions regarding Alzheimer’s care, including whether routine screening is advisable, what tests should be ordered, which interventions (including nonpharmacologic options) are worth considering, and how best to counsel patients and families about end-of-life care.

Routine screening? Still subject to debate

In considering routine dementia screening in primary care, the key question is whether screening improves outcomes. Advocates note that individuals with dementia may appear unimpaired during office visits and may not report symptoms due to lack of insight; they point out, too, that waiting for an event that makes cognitive impairment obvious, such as a driving mishap, is risky. Those who advocate routine screening also note that only about half of those who have dementia are ever diagnosed.

Others, including the US Preventive Services Task Force (USPSTF), disagree. In its 2014 evidence review, the USPSTF indicated that there is “insufficient evidence to assess the balance of benefits and harms of screening for cognitive impairment in older adults.”

Mixed messages

The dearth of evidence is also reflected in the conflicting recommendations of the Affordable Care Act (ACA) and the Centers for Health Care Quality and Transparency.
Medicare and Medicaid Services (CMS). The ACA requires physicians to assess the cognitive function of Medicare patients during their annual wellness visits. CMS, however, instructs providers to screen for dementia only if observation or concerns raised by the patient or family suggest the possibility of impairment, and does not recommend any particular test.5

Cost-effectiveness analyses raise questions about the value of routine screening, as well. Evidence suggests that if a primary care physician screens 300 older patients, 39 will have a positive screen. But only about half of those 39 will agree to a diagnostic evaluation, and no more than 9 will ultimately be diagnosed with dementia. The estimated cost of identifying 9 cases is nearly $40,000—all in the absence of a treatment to cure or stop the progression of the disorder.6

The bottom line: Evidence does not support routine dementia screening of older adults. When cognitive impairment is suspected, however, physicians should conduct a diagnostic evaluation—and consider educating patients and families about the Alzheimer’s Association (AA)’s 10 warning signs of AD.7 (See “Is it Alzheimer’s? 10 warning signs”7 on page 12.) A longer version, available at http://www.alz.org/national/documents/checklist_10signs.pdf, outlines the cognitive changes that are characteristic of healthy aging and compares them to changes suggestive of early dementia.7

How to proceed when you suspect AD

Step 1: Screening instrument. The first step in the diagnostic evaluation of a patient with suspected AD is to determine if, in fact, cognitive impairment is present. This can be done by screening with in-office screening instruments, such as the Mini-Cog (available at alz.org/documents_custom/minicog.pdf) or Mini-Mental State Examination (MMSE; health.gov.bc.ca/pharmacare/adti/clinician/pdf/ADTI%20SMMSE-GDS%20Reference%20Card.pdf), among others.8

Step 2: Clinical evaluation. If observation and test results suggest cognitive impairment, the next step is to determine whether clinical findings are consistent with the diagnostic criteria for AD (TABLE 1)9 developed by workgroups from the National Institute on Aging (NIA)/AA in 2011. A work-up is necessary to identify conditions that can mimic dementia (eg, depression) and behaviors that suggest another type of dementia, such as frontotemporal or Lewy body dementia.10 Lab testing should be included to rule out potentially reversible causes of cognitive dysfunction (eg, hypothyroidism, vitamin D deficiency).

Step 3: Neuropsychological evaluation. The NIA/AA recommends neuropsychological testing when the brief cognitive tests, history, and clinical work-up are not sufficient for a definitive diagnosis of dementia.9 This generally involves a referral to a neuropsychologist, who conducts a battery of standardized tests to evaluate attention, memory, language, visual-spatial abilities, and executive functions, among others. Neuropsychological testing can confirm the presence of cognitive impairment and aid in the differential diagnosis by comparing the patient’s performance in these domains with characteristic features of different dementia syndromes.

Step 4: Brain imaging. With either computed tomography or magnetic resonance imaging can be included in the work-up for patients with suspected AD to rule out abnormalities—eg, metastatic cancer, hydrocephalus, or occult chronic subdural hematoma—that could be causing cognitive impairment.9,10 Clinical features that generally warrant brain imaging include onset of cognitive impairment before age 60; unexplained focal neurologic signs or symptoms; abrupt onset or rapid decline; and/or predisposing conditions, such as cancer or anticoagulant treatment.10

The role of biomarkers and advanced brain imaging

Biomarkers that might provide confirmation of AD in patients who exhibit early symptoms of dementia have been studied extensively.11 The NIA/AA identified 2 categories of AD biomarkers:

- tests for β-amyloid deposition in the brain, including spinal fluid assays for β-amyloid (Aβ42) and positron emission tomography (PET) scans after...
When communicating an Alzheimer’s disease diagnosis, prioritize information and offer emotional support.

Is it Alzheimer’s?
10 warning signs
1. Memory loss that disrupts daily life
2. Challenges in planning or solving problems
3. Difficulty completing familiar tasks
4. Confusion with time or place
5. Trouble understanding visual images and spatial relationships
6. New problems with words in speaking or writing
7. Misplacing things and losing the ability to retrace steps
8. Decreased or poor judgment
9. Withdrawal from work or social activities
10. Changes in mood and personality

When evidence indicates an AD diagnosis
When faced with the need to communicate an AD diagnosis, follow the general recommendations for delivering any bad news or discouraging prognosis:

- **Prioritize and limit the information you provide,** determining not only what the patient and family want to hear, but also how much they are able to comprehend.
- **Confirm that the patient and family understand** the information you’ve provided.
- **Offer emotional support** and recommend additional resources (TABLE 2).

Mild cognitive impairment: How likely that it will progress?
Along with diagnostic criteria for AD, the NIA/AA developed criteria for a symptomatic predementia phase of AD—often referred to as MCI. According to the workgroup, MCI is diagnosed when:

- the patient, an informant, or a clinician is concerned about the individual’s cognitive decline from previous levels of functioning;
- there is evidence of cognitive impairment, ideally through psychometric testing, revealing performance below expectation based on the patient’s age and education;
- the patient is able to maintain independent functioning in daily life, despite mild problems or the need for minimal assistance; and
- there is no significant impairment in social or occupational functioning.

Progression: Less likely than you might think
Patients with MCI are at risk for progression to overt dementia, with an overall annual conversion rate from MCI to dementia estimated at 10% to 15%. This estimate must be interpreted with caution, however, because most studies were conducted prior to the 2011 guidelines, when different diagnostic criteria were used. Observers have noted, too, that the numbers largely reflect data collected in specialty clinics and that community-based studies reveal substantially lower conversion rates (3%-6% per year). In addition, evidence suggests that many patients with MCI demonstrate long-term stability or even reversal of deficits.

While there is some consideration of the use of biomarkers and amyloid imaging tests to help determine which patients with MCI will progress to AD, practice guidelines do not currently recommend such testing and it is not covered by Medicare.

Intravenous injection of florbetapir or flutemetamol, which bind to amyloid in the brain; and
- tests for neuronal degeneration, which would include spinal fluid assays for tau protein and PET scans after injection of fluorodeoxyglucose (FDG), which shows decreased uptake in patients with AD.

Research reveals the promise of these biomarkers as diagnostic tools, particularly in patients with an atypical presentation of dementia or mild cognitive impairment (MCI) that may be associated with early AD. However, the NIA/AA concluded that additional research is needed to validate these tests for routine diagnostic purposes. Medicare covers PET scans with FDG only for the differential diagnosis of AD vs frontotemporal dementia.

When communicating an Alzheimer’s disease diagnosis, prioritize information and offer emotional support.

<table>
<thead>
<tr>
<th>Is it Alzheimer’s? 10 warning signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Memory loss that disrupts daily life</td>
</tr>
<tr>
<td>2. Challenges in planning or solving problems</td>
</tr>
<tr>
<td>3. Difficulty completing familiar tasks</td>
</tr>
<tr>
<td>4. Confusion with time or place</td>
</tr>
<tr>
<td>5. Trouble understanding visual images and spatial relationships</td>
</tr>
<tr>
<td>6. New problems with words in speaking or writing</td>
</tr>
<tr>
<td>7. Misplacing things and losing the ability to retrace steps</td>
</tr>
<tr>
<td>8. Decreased or poor judgment</td>
</tr>
<tr>
<td>9. Withdrawal from work or social activities</td>
</tr>
<tr>
<td>10. Changes in mood and personality</td>
</tr>
</tbody>
</table>

Is it Alzheimer’s?
10 warning signs

1. Memory loss that disrupts daily life
2. Challenges in planning or solving problems
3. Difficulty completing familiar tasks
4. Confusion with time or place
5. Trouble understanding visual images and spatial relationships
6. New problems with words in speaking or writing
7. Misplacing things and losing the ability to retrace steps
8. Decreased or poor judgment
9. Withdrawal from work or social activities
10. Changes in mood and personality
Given the progressive cognitive decline that characterizes AD, it is important to address the primary caregiver’s understanding of, and ability to cope with, the disease. It is also important to explore beliefs and attitudes regarding AD. Keep in mind that different cultural groups tend to differ in their beliefs about the nature, cause, and appropriate management of AD, as well as the role of spirituality, help-seeking, and stigma.19,20

The progressive and ultimately fatal nature of AD also makes planning for the future a priority. Ideally, patients should be engaged in discussions regarding end-of-life care as early as possible, while they are still able to make informed decisions and express their preferences. Discussing end-of-life care can be overwhelming for newly diagnosed patients and their families, however, so it is important that you address issues—medical, financial, and legal planning, for example—that families should be considering.

**Drugs address cognitive and behavioral function**

No currently available treatments can cure or significantly alter the progression of AD, but 2 classes of medications are used to improve cognitive function.

---

**TABLE 1**

Clinical criteria for a probable Alzheimer’s diagnosis

<table>
<thead>
<tr>
<th>Patient must meet criteria for a dementia diagnosis:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cognitive or behavioral symptoms must:</td>
</tr>
<tr>
<td>a. interfere with ability to function</td>
</tr>
<tr>
<td>b. represent a decline from previous levels of functioning: <strong>and</strong></td>
</tr>
<tr>
<td>c. are not explained by delirium or major psychiatric disorder.</td>
</tr>
<tr>
<td>2. Cognitive impairment must be diagnosed through a combination of:</td>
</tr>
<tr>
<td>a. history by patient/informant <strong>and</strong></td>
</tr>
<tr>
<td>b. bedside mental status exam or neuropsychological testing.</td>
</tr>
<tr>
<td>3. Cognitive or behavioral impairment must involve 2 or more of the following domains:</td>
</tr>
<tr>
<td>a. ability to acquire and remember new information</td>
</tr>
<tr>
<td>b. reasoning, judgment, and handling of complex tasks</td>
</tr>
<tr>
<td>c. visuospatial abilities</td>
</tr>
<tr>
<td>d. language function</td>
</tr>
<tr>
<td>e. personality or behavior.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient must also meet criteria for probable AD:*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Dementia must have insidious onset (months to years) <strong>and</strong></td>
</tr>
<tr>
<td>2. have worsening course by report or observation.</td>
</tr>
</tbody>
</table>

AD, Alzheimer’s disease.

*Probable AD is **not** diagnosed if there is evidence of substantial cerebrovascular disease, core features of other dementias, or evidence of other neurologic or non-neurologic comorbidities or medication that can affect cognition.

In patients with dementia, the effects of ChEIs and NMDA receptor blockers on cognition are statistically significant but modest, and are often of questionable clinical relevance.

NMDA receptor blockers have an effect on progression from MCI to dementia.21,22 Neither class is FDA-approved for treating MCI.

In patients with dementia, the effects of ChEIs and NMDA receptor blockers on cognition are statistically significant but modest, and often of questionable clinical relevance.23 Nonetheless, among ChEIs, donepezil is approved by the US Food and Drug Administration (FDA) for mild, moderate, and severe dementia and galantamine and rivastigmine are approved for mild and moderate dementia. There is no evidence that any one ChEI is more effective than any other,24 and the choice of drugs is often guided by cost, adverse effects, and health plan formularies. Memantine, the only FDA-approved NMDA receptor blocker, is approved for moderate to severe dementia and can be used alone or in combination with a ChEI.

If these drugs are used in an attempt to improve cognition in AD, guidelines recommend the following approach for initial therapy: Prescribe a ChEI for the mild stage, a ChEI plus memantine for the moderate stage, and memantine (with or without a ChEI) for the severe stage.25 The recommendations also include monitoring every 6 months.

There is no consensus about when to discontinue medication. Various published recommendations call for continuing treatment until the patient has “lost all cognitive and functional abilities;”22 until the patient’s MMSE score falls below 10 and there is no indication that the drug is having a “worthwhile effect;”21 or until he or she has reached stage 7 on the Reisberg Functional Assessment Staging scale, indicating nonambulatory status with speech limited to one to 5 words a day.10

### Behavioral function

A variety of drugs are used to treat behavioral symptoms in AD. While not FDA-approved for this use, the most widely prescribed agents are second-generation antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone). The main effect of these drugs is often nothing more than sedation, and one large multisite clinical trial concluded that the adverse effects offset the benefits for patients with

<table>
<thead>
<tr>
<th>Issue</th>
<th>Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>Alzheimer’s and Dementia Caregiver Center</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.alz.org/care/overview.asp">http://www.alz.org/care/overview.asp</a></td>
</tr>
<tr>
<td></td>
<td>NIA Alzheimer’s Disease Education and Referral Center</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.nia.nih.gov/alzheimers/">http://www.nia.nih.gov/alzheimers/</a></td>
</tr>
<tr>
<td>Planning (medical, financial, legal)/benefits</td>
<td>AARP Caregiving Resource Center</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.aarp.org/home-family/caregiving">http://www.aarp.org/home-family/caregiving</a></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s Association Alzheimer’s Navigator</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.alzheimersnavigator.org/">https://www.alzheimersnavigator.org/</a></td>
</tr>
<tr>
<td></td>
<td>National Council on Aging Benefits Checkup</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.benefitscheckup.org/">https://www.benefitscheckup.org/</a></td>
</tr>
<tr>
<td>Safety</td>
<td>Association for Driver Rehabilitation Specialists: Driving and Alzheimer’s/Dementia</td>
</tr>
<tr>
<td></td>
<td>NIA’s Home Safety for People with Alzheimer’s booklet</td>
</tr>
<tr>
<td>Support</td>
<td>Caregiver Action Network</td>
</tr>
<tr>
<td></td>
<td><a href="http://caregiveraction.org/">http://caregiveraction.org/</a></td>
</tr>
</tbody>
</table>

AD, Alzheimer’s disease; NIA, National Institute on Aging.
Indeed, the FDA has issued an advisory on the use of second-generation antipsychotics in AD patients, stating that they are associated with an increased risk of death. The recently updated Beers Criteria strongly recommend avoiding these drugs for treating behavioral disturbances in AD unless nonpharmacologic options have failed and the patient is a threat to self or others.

Because of the black-box warning that antipsychotics increase the risk of death, some physicians have advocated obtaining informed consent prior to prescribing such medications. At the very least, when family or guardians are involved, a conversation about risks vs benefits should take place and be documented in the medical record.

Other drug classes are also sometimes used in an attempt to improve behavioral function, including anti-seizure medications (valproic acid, carbamazepine), antidepressants (trazodone and selective serotonin reuptake inhibitors), and anxiolytics (benzodiazepines and buspirone). Other than their sedating effects, there is no strong evidence that these drugs are effective for treating dementia-related behavioral disorders. If used, caution is required due to potential adverse effects.

Nonpharmacologic management is “promising”

A recent systematic review of nonpharmacologic interventions for MCI evaluated exercise, training in compensatory strategies, and engagement in cognitively stimulating activities and found “promising but inconclusive” results. The researchers found that studies show mostly positive effects on cognition but have significant methodologic limitations. Importantly, there is no evidence of delayed or reduced conversion to dementia.

For patients who already have mild-to-moderate dementia, cognitive stimulation seems to help in the short term. There is also some evidence that exercise and occupational therapy may slow functional decline, but the effects are small to modest and their actual clinical significance (eg, the ability to delay institutionalization) is unclear. There is promising but preliminary evidence that cognitive rehabilitation (helping patients devise strategies to complete daily activities) may improve functioning in everyday life.

While behavioral symptoms are often due to the dementia itself, it is important to identify and treat medical and environmental causes that may be contributing, such as infection, pain, and loud or unsafe environments. As noted before, nonpharmacologic treatments are generally preferred for behavioral problems and should be considered prior to drug therapy. Approaches that identify and modify both the antecedents and consequences of problem behaviors and increase pleasant events have empirical support for the management of behavioral symptoms. Interventions including massage therapy, aromatherapy, exercise, and music therapy may also be effective in the short term for agitated behavior.

Caregivers should be encouraged to receive training in these strategies through organizations like AA. Caregiver education and support can reduce caregivers’ distress and increase their self-efficacy and coping skills.

### TABLE 3

<table>
<thead>
<tr>
<th>Criteria include all of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inability to walk, dress, or bathe without assistance</td>
</tr>
<tr>
<td>Intermittent or constant urinary or fecal incontinence</td>
</tr>
<tr>
<td>No consistent meaningful verbal communication; speech is limited to 6 or fewer intelligible words or only stereotypical phrases (eg, OK, thank you)</td>
</tr>
</tbody>
</table>

and one or more of the following within the past 12 months:

- Aspiration pneumonia
- Decubitus ulcers, multiple, stages III-IV
- Fever, recurrent after antibiotics
- Inability to maintain sufficient fluid and calorie intake, with 10% weight loss during the previous 6 months, or serum albumin <2.5 g/dL
- Pyelonephritis or upper UTI
- Septicemia

UTI, urinary tract infection.

The FDA has issued an advisory on the use of second-generation antipsychotics in Alzheimer’s patients, stating that they are associated with an increased risk of death.
end-of-life care must be addressed

Perhaps the most important aspect of end-of-life care in AD is assuring that families (or health care proxies) understand that AD is a fatal illness, with most patients dying within 4 to 8 years of diagnosis.1 Evidence indicates that patients whose proxies have a clear recognition of this are less likely to experience “burdensome” interventions such as parenteral therapy, emergency department visits, hospital admissions, and tube feedings in their last 3 months of life.5

Overall, decisions regarding discontinuing medical treatments in advanced AD should be made by balancing the likelihood of benefit with the potential for adverse effects.38 For example, the American Geriatrics Society recently recommended against feeding tubes because they often result in discomfort due to agitation, use of restraints, and worsening pressure ulcers.39

Unfortunately, only a minority of families receives straightforward information on the course and prognosis of AD, including the fact that patients eventually stop eating and that the natural cause of death is often an acute infection. Studies also show that patients with dementia are at risk for inadequate treatment of pain.40 Assuring adequate pain control is an essential component of end-of-life care.

Hospice. End-of-life care can often be improved with hospice care. This service is underused by patients with dementia, even though hospice care is available at no cost through Medicare. Hospice eligibility criteria for patients with AD are shown in Table 3.41,42

Finally, a word about prevention
Numerous risk factors have been associated with an increased risk of AD (Table 4).2,3 Some, like age and genetics, are nonmodifiable, while others—particularly cardiovascular risk factors—can be modified.1 There are also factors associated with decreased risk, most notably, physical exercise and participating in cognitively stimulating activities.3 Identification of these factors has led to the hope that addressing them can prevent AD.

But association does not equal causation. In 2010, a report from the National Institutes of Health concluded that, although there are modifiable factors associated with AD, there is insufficient evidence that addressing any of them will actually prevent AD.43 In fact, there is good evidence that some of these factors (eg, statin therapy) are not effective in reducing the incidence of dementia, and that others (eg, vitamin E and estrogen therapy) are potentially harmful.44

The absence of empirically supported preventive interventions does not mean,
however, that we should disregard these risks and protective factors. Encouraging social engagement, for example, may improve both emotional health and quality of life. Addressing cardiovascular risk factors can reduce the rate of coronary and cerebrovascular disease, potentially including vascular dementia, even if it does not reduce the rate of AD.

Studies are evaluating the use of monoclonal antibodies with anti-amyloid properties for preventing AD in individuals who have APOE ε4 genotypes or high amyloid loads on neuroimaging. It will be several years before results are available, however, and the outcome of these studies is uncertain as the use of anti-amyloid agents for treating established dementia has not been effective.

References


CORRESPONDENCE

Marisa Menchola, PhD, Department of Psychiatry, University of Arizona College of Medicine, 1501 N. Campbell Ave., 706C. Tucson, AZ 85724; marism@psychiatry.arizona.edu

The progressive and ultimately fatal nature of Alzheimer’s disease makes planning for the future a priority.


